Skip to main content

Mazelsky Jonathan Jay's Form 4 filing

IDEXX Laboratories Inc (IDXX) · filed Nov 16, 2022

Accession no.
0001567619-22-020466
Filed
Nov 16, 2022
Trade date
Nov 14, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.56M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mazelsky Jonathan JayCIK 0001556270Director, Officer (President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 14, 2022Common StockMOption exerciseAcquired+18,998$62.00+$1,177,87681,304.64Direct
Nov 14, 2022Common StockSSaleDisposed−972$433.37F1−$421,235.6480,332.64Direct
Nov 14, 2022Common StockSSaleDisposed−6,385$434.26F2−$2,772,750.173,947.64Direct
Nov 14, 2022Common StockSSaleDisposed−2,543$435.07F3−$1,106,383.0171,404.64Direct
Nov 14, 2022Common StockSSaleDisposed−600$435.88F4−$261,52870,804.64Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 14, 2022Common StockMOption exerciseDisposed−18,998–F6–0Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the weighted average price of the shares sold ranging from a low of $432.67 to a high of $433.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

F2

Represents the weighted average price of the shares sold ranging from a low of $433.69 to a high of $434.685 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average price of the shares sold ranging from a low of $434.70 to a high of $435.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average price of the shares sold ranging from a low of $435.77 to a high of $436.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

F6

Not applicable.

Referenced by the price of 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)